Porcine Epidemic Diarrhea Vaccines Market Report 2025

This Porcine Epidemic Diarrhea Vaccines market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The porcine epidemic diarrhea vaccines market size has grown strongly in recent years. It will grow from $1.67 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to large-scale vaccination campaigns, expanded programs on immunization (EPI), the adoption of disposable syringes, diarrhea eradication efforts, and initiatives like the global alliance for vaccines and immunization (GAVI).

The porcine epidemic diarrhea vaccines market size is expected to see strong growth in the next few years. It will grow to $2.42 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to the growing emphasis on immunization programs, expanded vaccine development pipelines, expanding pig populations, focus on cold chain management, and rising awareness about the importance of preventive healthcare measures. Major trends in the forecast period include continued innovations in vaccine delivery device technology, focus on needle-free solutions, advancements in personalized medicine, growing preference for self-administered vaccines, and strengthening animal healthcare infrastructure and distribution networks.

The growth of the porcine epidemic diarrhea (PED) vaccine market is expected to be driven by the rising pig farming industry. Pig farming encompasses the raising of domestic pigs for meat production, breeding, rearing, managing them from birth to market weight, and marketing and selling pork products. The expansion of pig farming is fueled by the growing global demand for pork, improvements in breeding and management practices, advancements in farming technology, and the expanding markets for pork consumption. PED vaccines play a crucial role in preventing and managing outbreaks in pig farming. These vaccines are typically administered through injection or orally, starting during the sow's gestation period, to provide passive immunity to newborn piglets via colostrum. For example, the United States Department of Agriculture reported that in 2022, pork production in the U.S. reached 40.6 billion pounds, marking a 1 percent increase compared to the previous year. Consequently, the growth of pig farming is a key factor driving the demand for porcine epidemic diarrhea vaccines.

Leading companies in the porcine epidemic diarrhea vaccines sector are focusing on innovation to strengthen their market positions. One notable development is the introduction of the porcine parvovirus (PPV) vaccine, designed to prevent reproductive failures in pigs caused by PPV. Boehringer Ingelheim launched the ReproCyc ParvoFLEX vaccine in March 2022, which offers comprehensive protection against infertility, stillbirths, mummified fetuses, and weak piglets resulting from PPV. This innovative vaccine underscores the company's commitment to enhancing the health and productivity of pig herds through advanced formulation and efficacy.

In November 2024, Phibro Animal Health Corporation, a US-based health company, acquired Zoetis Inc. for an undisclosed amount. This acquisition is intended to expand Phibro’s product offerings in medicated feed additives and water-soluble products for cattle, swine, and poultry, enhancing its ability to support global animal health and nutrition. Additionally, the acquisition aims to boost Phibro’s profitability, grow its revenue base, and provide capital for future investments in the animal health sector. Zoetis Inc. is a pharmaceutical manufacturer specializing in the production of vaccines for porcine epidemic diarrhea.

Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, Elanco Animal Health, Idexx Laboratories Inc., Bio-Rad Laboratories Inc., Ceva Santé Animale Health Company, Phibro Animal Health Corporation, Benchmark Animal Health Ltd., IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Tecnovax, Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Komipharm International Co. Ltd., Boehringer Ingelheim Animal Health, MSD Animal Health, Ourofino Saúde Animal, Medgene Labs, Harrisvaccines Inc.

Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2024. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the porcine epidemic diarrhea vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Porcine epidemic diarrhea (PED) vaccines are formulated to confer immunity against the porcine epidemic diarrhea virus (PEDV), which causes severe gastrointestinal illness in pigs. These vaccines play a crucial role in preventing and managing outbreaks of Porcine Epidemic Diarrhea, thereby safeguarding the health and productivity of pig populations and ensuring the economic stability of the swine industry.

The primary types of porcine epidemic diarrhea vaccines are live vaccines and killed vaccines. Live vaccines contain attenuated or weakened forms of the PEDV virus. They are utilized in diverse settings, including piglets and adult pigs, across veterinary hospitals and hog production farms.

The porcine epidemic diarrhea vaccines market research report is one of a series of new reports that provides porcine epidemic diarrhea vaccines market statistics, including porcine epidemic diarrhea vaccines industry global market size, regional shares, competitors with a porcine epidemic diarrhea vaccines market share, detailed porcine epidemic diarrhea vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the porcine epidemic diarrhea vaccines industry. This porcine epidemic diarrhea vaccines research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The porcine epidemic diarrhea vaccines market consists of sales of ingelvac PEDV, barricade, PED vax, PEDV shield, and enterisol ileitis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.